Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218310 | 0.90 | HSP90AA1 (0.56) | HSP90AA1PDK1NR3C2NPC1RAB9A | |
| SCHEMBL1218740 | 0.90 | HSP90AA1 (0.73) | HSP90AA1PDK1PDK2PDK3PDK4 | |
| SCHEMBL1219578 | 0.89 | HSP90AA1 (0.57) | HSP90AA1NR3C2HSP90AB1PDE11A | |
| SCHEMBL1219002 | 0.89 | HSP90AA1 (0.59) | HSP90AA1PDK1PDK2PDK3PDK4 | |
| SCHEMBL1219136 | 0.88 | HSP90AA1 (0.61) | HSP90AA1PDK1HSP90AB1 | |
| SCHEMBL2076846 | 0.88 | HSP90AA1 (0.61) | HSP90AA1NR3C2HSP90AB1PDE11A | |
| SCHEMBL1217333 | 0.87 | HSP90AA1 (0.59) | HSP90AA1NR3C2NPC1RAB9AHSP90AB1 | |
| SCHEMBL1628864 | 0.87 | HSP90AA1 (0.69) | HSP90AA1NR3C2HSP90AB1PDE11A | |
| SCHEMBL1219192 | 0.86 | HSP90AA1 (0.60) | HSP90AA1PDK1HSP90AB1 | |
| SCHEMBL2080816 | 0.85 | HSP90AA1 (0.61) | HSP90AA1PDK1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018370-B1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-27 | — | — | EP | claimed |
| US-7906657-B2 | 1,5-diphenylpyrazoles II as HSP90 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2011-03-15 | — | — | US | claimed |
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-31 | — | — | US | claimed |
| EP-2018370-B1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-7906657-B2 | 1,5-diphenylpyrazoles II as HSP90 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20110028485-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | EGGENWEILER HANS-MICHAEL | 2011-02-03 | — | — | US | disclosed |
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885PDK1 336/4885PDK2 590/4885 |
| US-20110028485-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885PDK1 336/4885PDK2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.